Discovery of ((4R,5S)-5-amino-4-(2,4,5-trifluorophenyl)cyclohex-1-enyl)-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

被引：44

作者：

Pei, Zhonghua ^{[1
]}

Li, Xiaofeng ^{[1
]}

von Geldern, Thomas W. ^{[1
]}

Madar, David J. ^{[1
]}

Longenecker, Kenton ^{[1
]}

Yong, Hong ^{[1
]}

Lubben, Thomas H. ^{[1
]}

Stewart, Kent D. ^{[1
]}

Zinker, Bradley A. ^{[1
]}

Backes, Bradley J. ^{[1
]}

Judd, Andrew S. ^{[1
]}

Mulhern, Mathew ^{[1
]}

Ballaron, Stephen J. ^{[1
]}

Stashko, Michael A. ^{[1
]}

Mika, Amanda K. ^{[1
]}

Beno, David W. A. ^{[1
]}

Reinhart, Glenn A. ^{[1
]}

Fryer, Ryan M. ^{[1
]}

Preusser, Lee C. ^{[1
]}

Kempf-Grote, Anita J. ^{[1
]}

Sham, Hing L. ^{[1
]}

Trevillyan, James M. ^{[1
]}

机构：

[1] Abbott Labs, Global Pharmaceut Res & Dev, Metab Dis Res, Abbott Pk, IL 60064 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2006年 / 49卷 / 22期

关键词：

D O I：

10.1021/jm060955d

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Dipeptidyl peptidase IV (DPP4) deactivates glucose-regulating hormones such as GLP-1 and GIP, thus, DPP4 inhibition has become a useful therapy for type 2 diabetes. Optimization of the high-throughput screening lead 6 led to the discovery of 25 (ABT-341), a highly potent, selective, and orally bioavailable DPP4 inhibitor. When dosed orally, 25 dose-dependently reduced glucose excursion in ZDF rats. Amide 25 is safe in a battery of in vitro and in vivo tests and may represent a new therapeutic agent for the treatment of type 2 diabetes.

引用

页码：6439 / 6442

页数：4

共 31 条

[21] Discovery of 1-[3-aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808), a potent, efficacious and orally bioavailable inhibitor of blood coagulation factor Xa
Orwat, MJ
Fevig, JM
Quan, ML
Galemmo, RA
Amparo, E
Alexander, RS
Rossi, KA
Smallwood, AM
Wong, PC
Luettgen, JM
Knabb, RM
Bai, SA
He, K
Wexler, RR
Lam, PYS
Pinto, DJP
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2663 - U2663
[22] (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1H-1,2,4-triazo1-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950):: A rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor with reduced myotoxicity potential
Ahmad, Saleem
Madsen, Cort S.
Stein, Philip D.
Janovitz, Evan
Huang, Christine
Ngu, Khehyong
Bisaha, Sharon
Kennedy, Lawrence J.
Chen, Bang-Chi
Zhao, Rulin
Sitkoff, Doree
Monshizadegan, Hossain
Yin, Xiaohong
Ryan, Carol S.
Zhang, Rongan
Giancarli, Mary
Bird, Eileen
Chang, Ming
Chen, Xing
Setters, Robert
Search, Debra
Zhuang, Shaobin
Nguyen-Tran, Van
Cuff, Carolyn A.
Harrity, Thomas
Darienzo, Celia J.
Li, Tong
Reeves, Richard A.
Blanar, Michael A.
Barrish, Joel C.
Zahler, Robert
Robl, Jeffrey A.
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (09) : 2722 - 2733
[23] 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
Eckhardt, Matthias
Langkop, Elke
Mark, Michael
Tadayyon, Mob
Thomas, Leo
Nar, Herbert
Pfrengle, Waldemar
Guth, Brian
Lotz, Ralf
Sieger, Peter
Fuchs, Holger
Himmelsbach, Frank
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (26) : 6450 - 6453
[24] Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease
Sunose, Mihiro
Bell, Kathryn
Ellard, Katie
Bergamini, Giovanna
Neubauer, Gitte
Werner, Thilo
Ramsden, Nigel
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (14) : 4613 - 4618
[25] Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′- (methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa
Pinto, DJP
Orwat, MJ
Wang, SG
Fevig, JM
Quan, ML
Amparo, E
Cacciola, J
Rossi, KA
Alexander, RS
Smallwood, AM
Luettgen, JM
Liang, L
Aungst, BJ
Wright, MR
Knabb, RM
Wong, PC
Wexler, RR
Lam, PYS
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (04) : 566 - 578
[26] Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis
Wang, Xueqing
Liu, Bo
Searle, Xenia
Yeung, Clinton
Bogdan, Andrew
Greszler, Stephen
Singh, Ashvani
Fan, Yihong
Swensen, Andrew M.
Vortherms, Timothy
Balut, Corina
Jia, Ying
Desino, Kelly
Gao, Wenqing
Yong, Hong
Tse, Chris
Kym, Philip
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (04) : 1436 - 1449
[27] Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
Pinto, Donald J. P.
Orwat, Michael J.
Koch, Stephanie
Rossi, Karen A.
Alexander, Richard S.
Smallwood, Angela
Wong, Pancras C.
Rendina, Alan R.
Luettgen, Joseph M.
Knabb, Robert M.
He, Kan
Xin, Baomin
Wexler, Ruth R.
Lam, Patrick Y. S.
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (22) : 5339 - 5356
[28] Discovery of N-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834):: A potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa
Phillips, GB
Buckman, BO
Davey, DD
Eagen, KA
Guilford, WJ
Hinchman, J
Ho, E
Koovakkat, S
Liang, A
Light, DR
Mohan, R
Ng, HP
Post, JM
Shaw, KJ
Smith, D
Subramanyam, B
Sullivan, ME
Trinh, L
Vergona, R
Walters, J
White, K
Whitlow, M
Wu, S
Xu, W
Morrissey, MM
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (19) : 3557 - 3562
[29] Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)
Axten, Jeffrey M.
Medina, Jesus R.
Feng, Yanhong
Shu, Arthur
Romeril, Stuart P.
Grant, Seth W.
Li, William Hoi Hong
Heerding, Dirk A.
Minthorn, Elisabeth
Mencken, Thomas
Atkins, Charity
Liu, Qi
Rabindran, Sridhar
Kumar, Rakesh
Hong, Xuan
Goetz, Aaron
Stanley, Thomas
Taylor, J. David
Sigethy, Scott D.
Tomberlin, Ginger H.
Hassell, Annie M.
Kahler, Kirsten M.
Shewchuk, Lisa M.
Gampe, Robert T.
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (16) : 7193 - 7207
[30] 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): A potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A
Nishio, Yukihiro
Kimura, Hidenori
Sawada, Naoyuki
Sugaru, Eiji
Horiguchi, Masakuni
Ono, Michiko
Furuta, Yudai
Sakai, Mutsuko
Masui, Yumi
Otani, Misato
Hashizuka, Takahiko
Honda, Yayoi
Deguchi, Jiro
Nakagawa, Tsutomu
Nakahira, Hiroyuki
BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (18) : 5490 - 5499

← 1 2 3 4 →